- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00688272
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
13 de novembro de 2017 atualizado por: GlaxoSmithKline
A Phase I, Double-blind, Placebo and Observer-blind Positive Controlled, Randomized, Parallel Group Study in Healthy Subjects to Investigate the Photoirritant Potential of Eltrombopag
This study is designed to investigate the safety profile and the photoirritant potential of eltrombopag in healthy subjects.
The study is placebo- and positive controlled, randomized, parallel group with three treatment arms: eltrombopag (75 mg QD), placebo, and a positive control (ciprofloxacin, 500 mg BID).
Eltrombopag will be administered in a double-blind fashion with respect to placebo and the positive control, ciprofloxacin, will be administered under observer-blinded conditions.
Twelve to fifteen subjects will be recruited into each arm, to assure total enrollment of 36 evaluable subjects.
The primary endpoint is the photosensitizing potential of eltrombopag as measured by photoirritant index (PI) and change in minimum erythemal dose (MED) in comparison with placebo.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
36
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Dundee, Reino Unido, DD1 9SY
- GSK Investigational Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Healthy Caucasian male or females with no clinically significant abnormality identified by the physician by evaluation of medical history, physical examination, clinical laboratory tests or 12-lead ECG.
- Subjects were adult males or females between 18 and 65 years of age, inclusive.
- All female subjects of child bearing potential agreed to commit to one of the protocol approved methods of contraception, and that they were used consistently and in accordance with both the product label and the instructions of a physician. Female participants are not permitted to use Hormonal form of contraception (combined oral contraceptive pills etc) because of its known potential to induce photosensitivity.
- All male subjects agreed to abstain completely from (or use a condom during) sexual intercourse with a pregnant or lactating female.
- All male subjects with partner(s) who is /are able to have children agreed to use condom with spermicide from screening until 90 days after the last dose of study medication. In addition, their partner (s) had to also use one of the following forms of contraception until 90 days after last date of study medication:
- Hormonal contraception i.e. the pill or hormones given by injection or given under the skin.
- Diaphragm with spermicide
- Cervical cap or female condoms.
- An intrauterine device (a coil micro-insert).
- Intrauterine system (IUS) e-g Mirena coil
- Tubal ligation
- Body weight greater than or equal to 50 kg and body mass index within the range 19-29.9 kg/m2.
- A signed and dated written informed consent was obtained for the subject.
- Skin Type 1, 2, or 3 according to the dermatological scale presented in the study protocol (see Modular Appendices).
- Negative test for porphyrins, ANF, anti-Ro and anti-La (tests for lupus erythematosus) at screening.
- Liver function tests (LFTs; AST, ALT, ALP, bilirubin, gamma-GT) within the reference range, or deviations that were not considered clinically significant at screening by the investigator.
- Subjects who had a normal value of MED in comparison with the normal population databank at the photobiology unit, Dundee.
- The subject was able to understand and comply with protocol requirements and time tables, instructions and protocol-stated restrictions Exclusion Criteria
- Any abnormality identified on the screening medical assessment that in the opinion of the investigator and GlaxoSmithKline medical monitor could have been associated with an increased rish to the subject or could have interfered with study procedures.
- Subjects who had any sun or sunbed exposure to the skin of the back during the four weeks prior to the screening period.
- Subjects with history of polymorphic light eruption.
- Subjects who had a history of sensitivity to ciprofloxacin, any of the study medications or components thereof.
- Subjects with history of malignant melanoma in a first degree family member.
- Subjects with history of Gilbert Syndrome.
- Subjects with history of deep vein thrombosis or any other thromboembolic event.
- Subjects with history of sensitivity to heparin, or heparin-induced thrombocytopenia.
- Subjects with history of platelet clumping that prevents reliable measurement of platelet counts.
- Subjects with history of thrombocytopenia or bleeding due to abnormal platelet number or function.
- Subjects with C-reactive protein (CRP) that is elevated above normal range and considered clinically significant at screening.
- Subjects with history of myocardial infarction, stroke or sudden unexplained death in a first degree family member under the age of 60 years.
- Subjects with clotting factor abnormalities associated with hypercoagulability, specifically Factor V Leiden, Protein C, or Protein S deficiency, or antithrombin III deficiency.
- Subjects with haemoglobin, white blood cells, platelet count or reticulocyte count that are outside the reference range and considered clinically significant at screening by the investigator.
- Subjects with positive test for HIV, hepatitis B virus or hepatitis C virus.
- Subjects with positive urine drug screen including alcohol.
- Subjects with history of alcohol/drug abuse or dependence within 12 months of screening.
- History of regular alcohol consumption exceeding average weekly intake of greater than 21 units or an average daily intake of greater than three units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than two units (females). One unit is equivalent to a half-pint (220 mL) of beer/lager or one (25 mL) measure of spirits or one glass (125 mL) of wine.
- Subjects who could not refrain from smoking during the study period from Day-1 through the completion of follow-up assessments.
- Subjects who had received treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
- Subjects who had been exposed to more than four new chemical entities within 12 months prior to the first dosing day.
- Subjects who had taken any prescription or non-prescription drugs (including aspirin and NSAIDs), vitamins, herbal and dietary supplements, or any herbal remedies containing St. John's Wort within seven days (or 14 days if the drug is a potential enzyme inducer) or five half-lives (whichever is longer) prior to the first dose of study medication and through the completion of follow-up assessments. By exception, acetaminophen (or, paracetamol) at doses of less than or equal to 2 g/day and stable thyroid replacement therapy was allowed.
- Consumption of antacids (e.g., Maalox, Mylanta, Amphogel, Milk of Magnesia or TUMS™) within 48 h of the first dose of study medication and until the completion of follow-up assessments.
Subjects who had an clinically significant skin/allergic disease, including photo-allergy (excluding non
- active hay fever).
- Subjects with multiple tattoos which may have obscured skin reactions or which restricted the skin surface area available for testing.
- Subjects had to abstain from consumption of grapefruit, pomelo or Seville oranges from screening until the completion of follow-up assessments
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Arm 1
Eltrombopag 75 mg QD x 6 days
|
Given QD x 6 days
Outros nomes:
|
Comparador Ativo: Arm 2
Ciprofloxicin 500mg BID x 6 days
|
Given 500mg BID x 6 days
|
Comparador de Placebo: Arm 3
Placebo QD x 6 days
|
Given QD x 6 days
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Evaluate the photosensitizing potential, as measured by photoirritant index and change from baseline in minimum erythemal dose, of eltrombopag when dosed orally at 75 mg QD as compared to placebo and ciprofloxacin 500 mg BID.
Prazo: Screening - Day 8
|
Screening - Day 8
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Severity of phototoxic response Concentration of porphyrins, ANF, anti-Ro, and anti-La as measured on Day 6.
Prazo: Day 6
|
Day 6
|
Vital signs (blood pressure, heart rate, respiration rate and body temperature) taken after resting semi-supine position for at least 10 minutes;
Prazo: Screening, Days 1,2,3,4,5,6,7, and f/u
|
Screening, Days 1,2,3,4,5,6,7, and f/u
|
Clinical laboratory tests
Prazo: Screening, Day 1, 7 and f/u
|
Screening, Day 1, 7 and f/u
|
Assessment of AEs.
Prazo: Continuous trhoughout the study.
|
Continuous trhoughout the study.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
2 de junho de 2008
Conclusão Primária (Real)
25 de setembro de 2008
Conclusão do estudo (Real)
25 de setembro de 2008
Datas de inscrição no estudo
Enviado pela primeira vez
28 de maio de 2008
Enviado pela primeira vez que atendeu aos critérios de CQ
30 de maio de 2008
Primeira postagem (Estimativa)
2 de junho de 2008
Atualizações de registro de estudo
Última Atualização Postada (Real)
17 de novembro de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
13 de novembro de 2017
Última verificação
1 de novembro de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças do sistema imunológico
- Doenças autoimunes
- Doenças Hematológicas
- Hemorragia
- Distúrbios hemorrágicos
- Distúrbios da Coagulação Sanguínea
- Manifestações de pele
- Trombocitopenia
- Distúrbios das plaquetas sanguíneas
- Microangiopatias Trombóticas
- Púrpura
- Púrpura Trombocitopênica
- Púrpura Trombocitopênica Idiopática
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Inibidores da Topoisomerase II
- Inibidores da Topoisomerase
- Agentes antibacterianos
- Inibidores da enzima citocromo P-450
- Inibidores do citocromo P-450 CYP1A2
- Ciprofloxacina
Outros números de identificação do estudo
- TRA106914
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Eltrombopag
-
Novartis PharmaceuticalsConcluídoPúrpura Trombocitopênica IdiopáticaFederação Russa
-
Novartis PharmaceuticalsConcluído
-
GlaxoSmithKlineConcluídoPúrpura Trombocitopênica IdiopáticaAlemanha, Federação Russa
-
Groupe Francophone des MyelodysplasiesGlaxoSmithKline; NovartisConcluído
-
GlaxoSmithKlineConcluídoPúrpura Trombocitopênica IdiopáticaEstados Unidos, Taiwan, Itália, Polônia, Peru, Canadá, Dinamarca, Alemanha, Eslováquia, Espanha, Reino Unido, Nova Zelândia, China, Grécia, Hong Kong, Federação Russa, Áustria, Holanda, República Checa, França, Índia, Ucrânia, Tunísia, ... e mais
-
GlaxoSmithKlineConcluídoPúrpura Trombocitopênica IdiopáticaItália, Alemanha, Hong Kong, Republica da Coréia, Estados Unidos, Paquistão, Federação Russa, Índia, República Checa, Hungria, França
-
University Hospital, LilleRecrutamentoLeucemia | Falha do EnxertoFrança
-
Novartis PharmaceuticalsRescindidoFunção de Enxerto FracaEspanha
-
GlaxoSmithKlineConcluídoPúrpura Trombocitopênica IdiopáticaEstados Unidos